The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Dyne Therapeutics. The maintained price target of $20 suggests that the analyst believes the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.